Scimex: Cytomegalovirus is a common herpesvirus that can cross the placenta, infect the fetus and cause damage to the developing brain. The
 retrospective observational study of 323 children with cerebral palsy 
reveals that 9.6 per cent had cytomegalovirus (CMV) DNA in blood taken 
from their newborn screening card. This proportion is much higher 
than the proportion of children with CMV detected in the newborn period 
in the general community, which is less than one per cent.
Further,
 it is six times greater than the proportion of children with cerebral 
palsy who have had congenital CMV reported as an attributable cause of 
their condition to the Australian Cerebral Palsy Register (1.5 per cent), and higher than a recent retrospective study of Caucasian children with cerebral palsy (1.5 per cent).
Congenital
 CMV infection has been estimated to occur in approximately 0.7 per cent
 of newborn infants of whom ten to 15 per cent exhibit signs of 
infection at birth. These infants carry a higher risk of permanent 
neurodevelopmental disabilities, including cerebral palsy.
It’s 
estimated that a further ten to 15 per cent of children with congenital 
CMV infection who are asymptomatic at birth will go on to develop 
neurologic signs and symptoms beyond the neonatal period, predominantly 
late-onset hearing loss.
Cerebral palsy
 is the most common physical disability of childhood, and has been 
associated with a number of risk factors, including intrauterine 
infections such as congenital CMV.
“Despite this known 
association, and estimates of neurologic disability from congenital CMV,
 few reports describe the prevalence and epidemiology of cerebral palsy 
associated with congenital CMV, said the study’s senior author, Professor Cheryl Jones of the University of Sydney’s Marie Bashir Institute of Infectious Diseases and Biosecurity.
“Defining
 the role of congenital CMV as a risk factor for cerebral palsy is 
important because it is the most common intrauterine infection in 
developed countries, is potentially preventable, and antiviral therapy 
post-natally can reduce the severity of adverse neurologic outcomes.”
Study leader, Dr Hayley Smithers-Sheedy
 of the University of Sydney’s Cerebral Palsy Alliance said: “This study
 serves as a timely reminder of the importance of CMV as a common 
intrauterine viral infection in developed countries and the potential 
for long-term consequences beyond the newborn period.
“More 
research is needed to investigate the mechanisms and contribution of 
congenital CMV to the causal pathways to cerebral palsy.”